Mark J. Forchette, president and CEO of Delphinus Medical Technologies. “SoftVue provides a comprehensive solution that enables providers to transform their patients’ clinical experience. Our relationship with Trinity Capital helps us make impactful investments in execution, to help our clinical partners embrace this innovation, and serve the unmet needs of patients with dense breast tissue that SoftVue was designed to address.”

As part of this round of financing, Henry Chen, Managing Partner, Delos Capital has joined the Instylla Board of Directors. “Instylla has demonstrated impressive progress, having already advanced its next-generation liquid embolic technology to human clinical studies. We are honored and thrilled to support Instylla as it continues developing breakthrough solutions that will meaningfully improve patient outcomes,” said Henry Chen.

Over the past 6 months, Persist AI has developed cutting- edge robotics that enables automated development of long-acting injectable formulations. Coupled with AI models, they are able to rapidly predict which formulations will release drugs in the body for a long time and reduce the number of injections that patients need.